Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04626414 · ClinicalTrials.gov registry record · Phase 1
Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers
A Phase 1 study, sponsored by Shield Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04626414 is a Phase 1 study that has completed, run by Shield Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT04626414, a Phase 1 study, has completed, sponsored by Shield Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the Pharmacokinetics (PK) of the new ferric maltol suspension, in adults, with the existing ferric maltol capsule.
Interventions
- DRUG Ferric maltol capsule
- DRUG Ferric maltol suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2020-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04626414
The ClinicalTrials.gov registry entry for NCT04626414 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shield Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferric maltol capsule is the first listed.
NCT04626414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04626414 about?
NCT04626414 is a clinical study titled "Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers". The purpose of the study is to compare the Pharmacokinetics (PK) of the new ferric maltol suspension, in adults, with the existing ferric maltol capsule.
What is the current status of trial NCT04626414?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-09-28. Estimated completion is 2020-11-13.
What interventions are being tested in trial NCT04626414?
The interventions under investigation include: Ferric maltol capsule (DRUG), Ferric maltol suspension (DRUG).
Who is sponsoring clinical trial NCT04626414?
This trial is sponsored by Shield Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.